The significant improvements of the treatment of hypertension started in the Sixties where the diurétique one and the alpha-adjusters were quickly put on the market. Since then we saw the arrival of several new classes of drugs for the treatment of this condition, beta-blockers, of the calcium antagonists, the inhibitors of C# and most recently AIIAs, or the antagonists of receiver of angiotensin II. AIIAs provide the excellent ordering of the blood pressure, and with the difference of other agents which went before them, have almost placebo-like the tolerability. With RU, MSD were first with launching on the market at the beginning of 1995 with strongly successful drug Generic Cozaar (losartan). Visit canadian meds shop to buy Cozaar online without prescription. Cozaar managed to develop and increase its own market, and the occasions increased quickly in the first years after launching. Seven years on and with six products combatant for occasions in this market, Sankyo must launch their own AIIA, olmesartan. Recent papers showed strong results for olmesartan (Benicar), indicating a higher blood pressure lowering the surplus of older AIIAs possibilities such as Cozaar (source: Clinical newspaper of hypertension - Oct. 2001). The doctors will have a greater choice of treatment, but a how much Benicar impact make will in this tight market? It is interesting to buy Cozaar, firstly against the other force three AIIAs, Aprovel (BMS-Sanofi), Amias (AstraZeneca-Takeda) and Diovan (Novartis), and secondly against both newer AIIAs, Micardis (Boehringer Ingelheim) and Teveten (Solvay). We can employ essential launching to examine the three principal parameters of the success of launching - conscience, retailer and prescribing, for the products on this interesting market. All AIIAs carried out the high levels of the launching of post of conscience immediately. Their selling campaigns were so strong that between 60 and 70% general practitioners of RU realized of each AIIA in the 6 months of the launching of products. Later in the cycle of launching, Diovan was the largest interpreter, carrying out the conscience of 90% after 2 years. Interesting, Micardis was the only AIIA not to increase its conscience in the second launching of post of year. Turning to look at the launching of post detailing on this market, we can see how the promotion of Novartis exceeded the efforts of the other companies. More than 80% of the RU of the general practitioners had been detailed in the first 12 months of launching of post, compared with 65% for Aprovel and Amias, and 50% for Cozaar and Teveten. In were conclusion, and in a more important manner, how these high conscience and high levels to detail connected to the catch of each product? Looking at the prescribing general practitioner, in the first twelve months of launching of post we see the execution Aprovel to exceed the others in the class. In the second place at the market, Aprovel had a great base of user after 12 months approximately of 32% general practitioners of the RU compared with the 20% appreciated by Cozaar and Amias. In the second launching of post of year, Cozaar firmly increased their base of user just as Amias and Diovan but with a little degree. It is interesting to note that Diovan, which carried out the conscience and to detail highest of AIIAs in the two years launching of post of period, less better carried out in terms of proportion of general practitioners employing during the same time, compared with Cozaar, Amias and Aprovel (four the AIIAs force and four first at the market). Micardis and Teveten, launched within a four months of other but two years after Amias, were successful. Although almost matching other AIIAs in terms of conscience and the retailer, the proportion of general practitioners employing these products was uniformly low. After the first 12 months, Micardis carried out the use of 16% general practitioners of RU, and Teveten only of 5%. On this basis, that the prospects will be they for olmesartan, launching over two years after Teveten? We turn now to the jigsaw to the glance on the current occasions in the market of AIIA. In the first years after the launching of Cozaar until the beginning of 1999, there was regular growth on the market for occasions of AIIA. From 1999 until earlier this year, this decreased growth, and occasions made the average approximately of 17.000 per month. Since the beginning of this year saw us a remarkable increase in the occasions, lower part 20.000 with more than 30.000 in less than six months. As leads this growth in the businesses for AIIAs and which do they benefit? This data will convince our customers that olmesartan's excellent efficacy and safety profile, as well as additional vascular protective effects, make it a first class choice for the management of a hypertensive patient." We will certainly be watching this market with interest. Buy Cozaar Online to treat of high blood pressure as well. Good luck.Friday, August 3, 2007
Latest News About How To Treat High Blood Pressure With Cozaar Online
The significant improvements of the treatment of hypertension started in the Sixties where the diurétique one and the alpha-adjusters were quickly put on the market. Since then we saw the arrival of several new classes of drugs for the treatment of this condition, beta-blockers, of the calcium antagonists, the inhibitors of C# and most recently AIIAs, or the antagonists of receiver of angiotensin II. AIIAs provide the excellent ordering of the blood pressure, and with the difference of other agents which went before them, have almost placebo-like the tolerability. With RU, MSD were first with launching on the market at the beginning of 1995 with strongly successful drug Generic Cozaar (losartan). Visit canadian meds shop to buy Cozaar online without prescription. Cozaar managed to develop and increase its own market, and the occasions increased quickly in the first years after launching. Seven years on and with six products combatant for occasions in this market, Sankyo must launch their own AIIA, olmesartan. Recent papers showed strong results for olmesartan (Benicar), indicating a higher blood pressure lowering the surplus of older AIIAs possibilities such as Cozaar (source: Clinical newspaper of hypertension - Oct. 2001). The doctors will have a greater choice of treatment, but a how much Benicar impact make will in this tight market? It is interesting to buy Cozaar, firstly against the other force three AIIAs, Aprovel (BMS-Sanofi), Amias (AstraZeneca-Takeda) and Diovan (Novartis), and secondly against both newer AIIAs, Micardis (Boehringer Ingelheim) and Teveten (Solvay). We can employ essential launching to examine the three principal parameters of the success of launching - conscience, retailer and prescribing, for the products on this interesting market. All AIIAs carried out the high levels of the launching of post of conscience immediately. Their selling campaigns were so strong that between 60 and 70% general practitioners of RU realized of each AIIA in the 6 months of the launching of products. Later in the cycle of launching, Diovan was the largest interpreter, carrying out the conscience of 90% after 2 years. Interesting, Micardis was the only AIIA not to increase its conscience in the second launching of post of year. Turning to look at the launching of post detailing on this market, we can see how the promotion of Novartis exceeded the efforts of the other companies. More than 80% of the RU of the general practitioners had been detailed in the first 12 months of launching of post, compared with 65% for Aprovel and Amias, and 50% for Cozaar and Teveten. In were conclusion, and in a more important manner, how these high conscience and high levels to detail connected to the catch of each product? Looking at the prescribing general practitioner, in the first twelve months of launching of post we see the execution Aprovel to exceed the others in the class. In the second place at the market, Aprovel had a great base of user after 12 months approximately of 32% general practitioners of the RU compared with the 20% appreciated by Cozaar and Amias. In the second launching of post of year, Cozaar firmly increased their base of user just as Amias and Diovan but with a little degree. It is interesting to note that Diovan, which carried out the conscience and to detail highest of AIIAs in the two years launching of post of period, less better carried out in terms of proportion of general practitioners employing during the same time, compared with Cozaar, Amias and Aprovel (four the AIIAs force and four first at the market). Micardis and Teveten, launched within a four months of other but two years after Amias, were successful. Although almost matching other AIIAs in terms of conscience and the retailer, the proportion of general practitioners employing these products was uniformly low. After the first 12 months, Micardis carried out the use of 16% general practitioners of RU, and Teveten only of 5%. On this basis, that the prospects will be they for olmesartan, launching over two years after Teveten? We turn now to the jigsaw to the glance on the current occasions in the market of AIIA. In the first years after the launching of Cozaar until the beginning of 1999, there was regular growth on the market for occasions of AIIA. From 1999 until earlier this year, this decreased growth, and occasions made the average approximately of 17.000 per month. Since the beginning of this year saw us a remarkable increase in the occasions, lower part 20.000 with more than 30.000 in less than six months. As leads this growth in the businesses for AIIAs and which do they benefit? This data will convince our customers that olmesartan's excellent efficacy and safety profile, as well as additional vascular protective effects, make it a first class choice for the management of a hypertensive patient." We will certainly be watching this market with interest. Buy Cozaar Online to treat of high blood pressure as well. Good luck.
